Predicine

Every year, approximately 1 in 8 men is diagnosed with prostate cancer, which represents about 13% of all cancer cases in men. As we mark September as #ProstateCancerAwarenessMonth, it's vital to raise awareness and enhance education about this disease. Early detection and timely treatment can greatly increase survival rates. Men, and anyone with a prostate, should be aware of the risk factors and symptoms, and seek medical advice if they have any concerns. Let's work together to promote early screening and improve outcomes. Read about how Predicine liquid biopsy technology innovation is impacting personalized prostate cancer care: BRCA-deficient metastatic prostate cancer has an adverse prognosis and distinct genomic phenotype. https://lnkd.in/gVtn8ZNn 

Join us at ESMO 2024 in Barcelona, Spain! Predicine is thrilled to be exhibiting at ESMO 2024 and showcasing 7 groundbreaking poster presentations!    Visit us at BOOTH #419 to discover how we are revolutionizing the MRD landscape with our cutting-edge tumor-informed and tumor-naive liquid biopsy technologies. Explore exciting collaboration opportunities in affordable and accessible liquid biopsy solutions for global clinical trials, CDx development, and patient testing across the US, EU, China, and the rest of the world.    Meet our team on site or virtually! Schedule a meeting with our team and see how Predicine technology can help contribute to your program. https://lnkd.in/gfAamv7U    Learn about Predicine and our innovative solutions: https://lnkd.in/gndzmpGH    #ESMO2024 #liquidbiopsy #oncology #MRD #Biotech #bladdercancer #prostatecancer #kidneycancer #precisionmedicine 

Discover how comprehensive genomic profiling liquid biopsy assay, PredicineCARE™, provides critical insights into treatment efficacy and resistance mechanisms in clinical trials. This study, recently published in Nature Medicine, underscores PredicineCARE™'s pivotal role in supporting Incyte's Phase II basket trial of the FGFR inhibitor pemigatinib, driving forward drug development.    Key Highlights:  • PredicineCARE™ identified FGFR mutations and fusions/rearrangements in blood, providing predictive insights into pemigatinib's effectiveness.  • PredicineCARE™ detected a broad spectrum of FGFR mutations and co-alterations in cancers, offering essential insights into resistance mechanisms.  • PredicineCARE™ uncovered emerging resistance mechanisms, with 86% of baseline blood FGFR detections aligning with tissue findings (n=14), delivering valuable insights into acquired resistance.    View the publication here: https://lnkd.in/g6J9K-Sk Further insights:  PredicineCARE™ received Breakthrough Device Designation (BDD) from the U.S. FDA on August 23, 2022. It is currently under CDx development in collaboration with Janssen Pharmaceutica NV. Click here to learn more: https://lnkd.in/gfAamv7U    #diagnostics #oncology #NGS #liquidbiopsy #ctDNA #CDx #cfDNA 

Discover how monitoring tumor fraction (TF) provides crucial insights into treatment response further reinforcing the value of our next-generation, tissue-free, actionable MRD assay, PredicineBEACON™, in tracking and predicting therapeutic efficacy within Roche's clinical trials for the KRAS G12C inhibitor, Divarasib, in this major breakthrough publication in Clinical Cancer Research, which builds on the significant findings from our previous studies in The New England Journal of Medicine and Nature Medicine.    Our latest study offers deep insights into circulating tumor DNA (ctDNA), specifically examining tumor fraction (TF) and KRAS G12C mutant allele frequency (AF). The analysis of baseline ctDNA profiles and the rapid dynamics observed in patients responding to Divarasib demonstrate a strong correlation with improved treatment outcomes.      Key Highlights:  • Tissue free, baseline blood informed MRD Profiling.   • Therapeutic response and PFS has been captured by PredicineBEACON™ MRD analysis.  • Tumor Fraction is precisely captured by PredicineBEACON™ MRD assay, which is further confirmed by the PredicineWES+™ across whole exome.   • PredicineBEACON™ identified ultra-low frequency ctDNA dynamic, offering clinical potential for treatment monitoring and resistance mechanisms.    PredicineBEACON™ continues to push the boundaries of precision oncology, delivering crucial molecular insights that propel the development and broader adoption of groundbreaking therapies such as Divarasib. Explore how our cutting-edge technology is shaping the future of cancer treatment and driving innovations that enhance therapeutic efficacy.    View the publication here: https://lnkd.in/gHGefM25    Predicine is committed to advancing cancer research and collaborates with leading pharmaceutical companies to transform insights into impactful therapies.    For additional information about Predicine and our biopharma solutions, click below to schedule a meeting with Predicine's team https://lnkd.in/gfAamv7U #diagnostics #oncology #NGS #liquidbiopsy #MRD #ctDNA #CDx 

Explore how Predicine's state-of-the-art liquid biopsy platforms provide comprehensive cancer analysis for treatment selection, response monitoring, and resistance detection in advanced HER2+ gastroesophageal adenocarcinoma patients. In collaboration with Dana-Farber Cancer Institute on the CAPOX BETR phase II trial, our innovative approach highlights the transformative impact of Predicine's ultra-sensitive genomic profiling, comprehensive methylation analysis, and whole genome based fragmentomic technologies in advancing personalized cancer care.    Key Highlights:  • HER2 Amplifications Accurately Detected in Plasma by PredicineCARE™.  • PredicineCARE™ and PredicineSCORE™ Predict Early Treatment Success.  • PredicineCARE™ ULTRA Monitors Resistance Mutations with Ultra-High Sensitivity.  • PredicineALERT™ Offers Comprehensive MRD Detection with whole Methylome Profiling    View the publication here: https://lnkd.in/dYW2_xXG   Predicine is committed to advancing cancer research and collaborates with leading pharmaceutical companies to transform insights into impactful therapies.    For more details about Predicine and out biopharma solutions, click below to schedule a meeting with the Predicine team: https://lnkd.in/gfAamv7U #diagnostics #oncology #NGS #liquidbiopsy #MRD #ctDNA #CDx 

Predicine is excited to announce our exhibition in the 2024 World Conference on Lung Cancer (WCLC) in San Diego, CA, from September 7th-10th. Join us at booth #1420 to explore our advanced liquid biopsy solutions, centralized lab network, and decentralized CDx and kit manufacturing capabilities for global clinical trials, biomarker discovery, and CDx development. Be sure to inquire about our latest poster to learn about the significant clinical efficacy and tolerable safety profile of high-dose furmonertinib in EGFR-mutated NSCLC patients with leptomeningeal metastasis (LM).  Highlights:   • Globally harmonized liquid biopsy technology: outperforming ctDNA and cfRNA solutions with numerous clinical publications    • MRD detection: personalized and actionable MRD (PredicineBEACON™) & generalized, methylation MRD (PredicineALERT™)    • Global operations: supporting multiple national clinical trials, CDx developments and commercialization      Connect with our team to learn how our accurate, accessible, and affordable liquid biopsy solutions can support your global clinical trials, companion diagnostics (CDx) development, and commercialization efforts in the US, China, and ROW.     Schedule a meeting with us here: https://lnkd.in/gfAamv7U Learn more about Predicine: https://lnkd.in/gndzmpGH #LungCancer #NSCLC #Diagnostics #Oncology #NGS #LiquidBiopsy #MRD #ctDNA #CDx

We are excited to present and exhibit at the 5th Biomarker and Companion Diagnostics Conference in London from June 20th – 21st.     Alexander Kuklin, Vice President for CDx and BioPharma Partnerships at Predicine, will present on day 1 of the conference and unveil how Predicine’s tumor-naive and tumor-informed MRD liquid biopsy solution may help advance your precision oncology programs.    Highlights:   • Outperforming ctDNA and cfRNA liquid biopsy technology  • Tumor-informed or tumor-agnostic minimal residual diseases (MRD) detection  • Global operations in support of clinical trial, CDx development and commercialization     Come and visit Booth #19 and discover our unique liquid biopsy solutions in support of global clinical trials, CDx development, and commercialization.    Schedule a meeting with the Predicine team: https://lnkd.in/gfAamv7U    Learn more about Predicine: https://lnkd.in/gndzmpGH    #diagnostics #oncology #NGS #liquidbiopsy #MRD #ctDNA #CDx 

Check out this new study using PredicineEPIC™ on day 4 at ASCO2024!  High-dose furmonertinib in patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastases: A real-world study.  The highlights of this poster presentation include: • Assessing the efficacy and safety of high-dose furmonertinib in patients with EGFR-mutated non-small cell lung cancer (NSCLC) and leptomeningeal metastases using real-world data.    • Methylation analysis of cfDNA in cerebrospinal fluid (CSF), detected by PredicineEPIC™, an NGS-based ctDNA methylation assay, could be used as objective indicators for LM, evaluation of treatment response and prognosis prediction.    Learn more: https://lnkd.in/gTPN7eP4 Schedule a meeting with the Predicine team: https://lnkd.in/gfAamv7U #ASCO24 #precisiononcology #diagnostics #NGS #liquidbiopsy #NSCLC #ctdna #EGFR #CSF #LM

We are thrilled to present five ctDNA studies on the third day of #ASCO24. These include Predicine's mutation- and methylation-based MRD research utilizing blood and urine samples in breast and bladder cancers, along with an ultra-sensitive ctDNA study for treatment selection in breast cancer. For more details click on the ctDNA studies listed below: ·       Tumor fraction and copy number burden from urinary cell-free tumor DNA (utDNA) to predict minimal residual disease prior to repeat-transurethral resection in high-risk non-muscle invasive bladder cancer (HR-NMIBC). [https://lnkd.in/gC44P4MM] ·       A phase 1 study of the small-molecule PD-L1 inhibitor INCB099280 in select advanced solid tumors: Updated safety, efficacy, and pharmacokinetics (PK) results. [https://lnkd.in/gjXNRAHT ·       Non-invasive detection of urothelial carcinoma through ensembled methylation profiles and fragmentomic patterns in urinary cell-free DNA. [https://lnkd.in/gesCD6PJ] ·       Real-world study of urine-based NGS liquid biopsy in organ preservation therapy of muscle-invasive bladder cancer (MIBC). [https://lnkd.in/gjVvRE7c] ·       Prognostic significance of ctDNA mutation analysis in patients with HER2-positive breast cancer undergoing neoadjuvant chemotherapy. [https://lnkd.in/g53vfRvb] ·       Clinical utility of an ultra-sensitive ctDNA NGS assay for the detection and monitoring in HR-positive, HER2-negative breast cancer. [https://lnkd.in/gQqwy-_Q] Come and visit Predicine Booth #14105 and explore Predicine's outperforming liquid biopsy solutions for global clinical trials, CDx development, and commercialization. Schedule a meeting with the Predicine team: https://lnkd.in/dTJ9tkAu

Exciting News from Predicine! Three studies were presented on day 2 of #ASCO24 featuring PredicineCARE™, PredicineSCORE™, and PredicineATLAS™. For more details click on the ctDNA studies listed below: · Phase 1 study of NB003, a broad-spectrum KIT/PDGFRα inhibitor, in patients with advanced gastrointestinal stromal tumors (GIST). [https://lnkd.in/gPcEp5C9] · Glioma monitoring via longitudinal intracranial cerebrospinal fluid cell-free DNA. [https://lnkd.in/gkzTi33f] · Clonal hematopoiesis of indeterminate potential (CHIP): Outcomes and adverse events in patients with solid tumors [https://lnkd.in/gNfSymcR] Come and visit Booth #14105 and discover our unique liquid biopsy solutions in support of global clinical trials, CDx development, and commercialization. Schedule a meeting with the Predicine team: https://lnkd.in/dTJ9tkAu #ASCO #precisiononcology #diagnostics #NGS #liquidbiopsy #GIST #ctdna #KIT #PredicineCARE